Pterygium, which is a fibrovascular overgrowth tissue of the conjunctiva, is a common ocular surface disorder worldwide, especially in China. 1 It is commonly triangular in shape and encroaches into the cornea, and originates from the degenerated conjunctiva and the underlying Tenon's capsule, resulting in abnormal fibrovascular tissue proliferation. 2 Many risk factors, such as sunny, hot, dry, windy, dusty climate, and smoky and tropical regions, are related to the pterygium. 1,2 Ultraviolet radiation is a major factor, that damages cell proliferation and induces abnormal cell proliferation, goblet cell hyperplasia, squamous metaplasia fibrosis, inflammation, angiogenesis and extracellular matrix breakdown. 3 The pathogenesis of pterygium still needs to be elucidated and deeply studied. To date, many surgical treatments have been performed on the pterygium including primary conjunctival closure, conjunctival autografts (CAs), limbal conjunctival autografts (LCAs), leaving bare sclera and amniotic membrane transplantation (AMT). [3][4][5] The main postoperative complication is recurrence; therefore, every effort should be directed in reducing the recurrence rate. However, no gold standard treatment for surgical procedures to completely prevent recurrence has been confirmed.

No abstract

No abstract